At Janssen, we are translating our understanding of the biology of underlying retinal diseases to develop needed therapies that preserve and enhance vision.
Janssen’s clinical-stage retinal portfolio includes leading product candidates for inherited retinal diseases XLRP and achromatopsia.
Janssen is also expanding into more common eye diseases, including age-related macular degeneration, diabetic retinopathy, and diabetic macular edema.
To view all of our sponsors, please click here